data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italian
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italian
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
CureVac
(NASDAQ:CVAC)
17.51
-0.94[-5.09%]
At close: May 25
17.51
00
After Hours: 4:00PM EDT
Day High/Low17.18 - 18.75
52 Week High/Low14.2 - 125.66
Open / Close18.55 / 17.51
Float / Outstanding72.1M / 187.1M
Vol / Avg.661.8K / 528.1K
Mkt Cap3.3B
P/E-
50d Avg. Price17.67
Div / Yield-
Payout Ratio-
EPS-
Total Float72.1M

CureVac (NASDAQ:CVAC), Quotes and News Summary

CureVac (NASDAQ: CVAC)

Day High/Low17.18 - 18.75
52 Week High/Low14.2 - 125.66
Open / Close18.55 / 17.51
Float / Outstanding72.1M / 187.1M
Vol / Avg.661.8K / 528.1K
Mkt Cap3.3B
P/E-
50d Avg. Price17.67
Div / Yield-
Payout Ratio-
EPS-
Total Float72.1M
Benzinga - Sponsored
Benzinga - 11 hours ago
Benzinga - 17 hours ago
Benzinga - 17 hours ago
Benzinga - 18 hours ago
Benzinga - Apr 28, 2022, 7:24AM
Benzinga - Apr 22, 2022, 8:00AM
Benzinga - Apr 21, 2022, 7:22AM
Benzinga - Apr 21, 2022, 7:09AM
Benzinga - Apr 11, 2022, 3:59PM
Benzinga - Mar 30, 2022, 3:27PM
Benzinga - Mar 30, 2022, 7:06AM
Benzinga - Mar 1, 2022, 9:29AM
Benzinga - Feb 10, 2022, 7:25AM
Benzinga - Jan 21, 2022, 12:18PM
Benzinga - Jan 21, 2022, 11:28AM
Benzinga - Jan 21, 2022, 7:02AM
Benzinga - Jan 18, 2022, 6:40AM
Benzinga - Jan 17, 2022, 11:54AM
Benzinga - Jan 10, 2022, 5:25AM
Benzinga - Jan 7, 2022, 4:16PM
load more
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-15
REV
Q1 2022Est.ActualSurprise
EPS-0.090
REV27.360M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

CureVac Questions & Answers

Q
How do I buy CureVac (CVAC) stock?
A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are CureVac's (CVAC) competitors?
A

There are no as such competitors for CureVac.

Q
What is the target price for CureVac (CVAC) stock?
A

The latest price target for CureVac (NASDAQ: CVAC) was reported by JMP Securities on Friday, April 22, 2022. The analyst firm set a price target for 37.00 expecting CVAC to rise to within 12 months (a possible 111.31% upside). 5 analyst firms have reported ratings in the last year.

Q
Current Stock Price for CureVac (CVAC)?
A

The stock price for CureVac (NASDAQ: CVAC) is $17.51 last updated May 25, 2022, 8:00 PM UTC.

Q
Does CureVac (CVAC) pay a dividend?
A

There are no upcoming dividends for CureVac.

Q
When is CureVac (NASDAQ:CVAC) reporting earnings?
A

CureVac’s Q2 earnings are confirmed for Monday, August 15, 2022.

Q
Is CureVac (CVAC) going to split?
A

There is no upcoming split for CureVac.

Q
What sector and industry does CureVac (CVAC) operate in?
A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.